Which Patients with Advanced Clear Cell Renal Cell Carcinoma Benefit Most from First-line Checkpoint Inhibitor Combination Regimens: A Meta-analysis of Individual Patient Data and Aggregate Data from Randomised Trials
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.